Research Field
The company owns the international leading technology. In addition to the conventional lentiviral vector system, we independently developed a novel lentiviral vector inducible expression system that can be used for a variety of cell and animal experiments.

Our own TELEVECTORTM Lentiviral vector Easy-high Production Kit is high-end biological intermediates, and it can overcome the difficulties in the lentiviral vector production process and condense into a simple reagent A and reagent B so that your production costs reduce. To coordinate the two reagents, we also provide customers with a special culture medium C to improve plasmid transfection efficiency and to guarantee the production of virus particles.

In the next five years the company will focus on the development of the new clinical model of treatment for various genetic diseases with gene and cell joint , and promote domestic such genes drugs to clinical. The major R & D team is carrying out the related topics about gene therapy for AIDS and hepatitis B by the use of lentiviral vectors. At the same time we are applying for the international patent of carriers and treatment programs, expected to become a dark horse in the international AIDS treatment drugs field.